Courtesy: Wikipedia
India's new intellectual property rights (IPR) policy attempts to address concerns of developed countries regarding India's patent regime, while also protecting public interest, especially that of generic drug producers. However, through this effort of a balancing act, India might have landed up pleasing neither the USTR or U.S. business and disappointing many in India's domestic industry and civil society.
Courtesy: ustr.gov
The Trans-Pacific Partnership has dropped strong Intellectual Property Rights regulations on India’s doorstep. The implications of these regulations could affect India’s own policies, as well as her global aspirations towards the potential Regional Comprehensive Economic Partnership.
Courtesy: MEA
The U.S. is urging India to alter its IPR regime, and the potential impact on prices in the pharmaceuticals sector is of concern to African countries that depend on India for low-cost generic medicines. The recent India-Africa Forum Summit in New Delhi sought to address this issue, but it will be a challenge for India to balance competing pressures.
Sharad Sharma, co-founder, iSpirt, talks about Prime Minister Modi’s visit to the Silicon Valley on September 27. In an in interview to Gateway House, he outlines the steps that would make Modi’s visit a success for Digital India campaign and other key issues.
Courtesy: John Fischer/Flickr
Prime Minister Narendra Modi's outreach to the influential Indian diaspora in Silicon Valley in September should be centered on creating an Indian ecosystem for tech start-ups
Courtesy: Alibaba, Xiaomi, Wechat
Less than two years ago most Indians would struggle to name a Chinese company. Fast forward to the present, Chinese smartphone company Xiaomi is on the tips of everyone’s tongue. Chinese internet giants Alibaba, Tencent and Xiaomi have emerged as investors and major players in India’s fast growing e-commerce and internet space. Their emergence marks a new and exciting area of cooperation and engagement between India and China
Courtesy: Wikipedia/Narendra Modi
Pressure for a unified public procurement framework is mounting on India from both within the country and internationally. While an integrated procurement structure is necessary, a broad policy architecture must precede the framing of any legislation
Courtesy: media.licdn.com
Widely heralded as a success that brought together U.S. and Indian pharma producers over a high-cost drug at affordable prices, the Gilead deal looked ideal. A closer examination shows there’s more to consider than just low costs before the deal can become a template
Courtesy: colorlibrary.blogspot.com
Even though the India-Latin America relationship is yet to realise its potential, there are unique initiatives bridging this gap. The landmark office of Tata Consultancy Services in Chennai, hailed for its energy efficiency, has been designed by two Uruguayan architects—an effort which represents the growing synergy
Earlier this year, Gilead Sciences, a California-based pharmaceutical company, made the headlines for an unusual, positive move in the fraught property rights space. It entered into a license agreement with seven Indian pharmaceutical companies to manufacture lower cost versions of Sovaldi, its popular Hepatitis C drug
